Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Clinical experience with an L-proline–stabilized 10 %intravenous immunoglobulin (Privigen®): real-life effectiveness and tolerability.
[severe combined immunodeficiency]
This
retrospective
study
evaluated
the
effectiveness
and
tolerability
in
clinical
practice
of
an
L-
proline-stabilized
10
%
intravenous
immunoglobulin
(
IVIG
;
Privigen
®
)
in
patients
with
primary
(
PID
)
or
secondary
immunodeficiency
(
SID
)
.
Patients
from
6
centers
in
Europe
and
the
US
were
treated
with
individually
determined
regimens
of
Privigen
®
for
≥
3
months
.
Serum
immunoglobulin
G
(
IgG
)
trough
levels
,
annualized
rates
of
infection
,
hospitalization
and
antibiotics
use
,
and
the
incidence
of
adverse
events
(
AEs
)
were
analyzed
.
Of
72
patients
,
three
infants
with
severe
combined
immunodeficiency
(
SCID
)
were
analyzed
separately
.
The
remaining
69
patients
(
52
.
2
%
male
;
median
age
38
years
[
range
:
0
.
1
-
90
.
0
]
)
with
PID
(
82
.
6
%
)
or
SID
(
17
.
4
%
)
received
a
mean
(
±
standard
deviation
)
Privigen
®
dose
of
532
 
±
 
250
mg
/
kg
/
month
resulting
in
trough
serum
IgG
levels
of
407
-
1
,
581
mg
/
dL
(
median
:
954
mg
/
dL
)
.
Ten
patients
(
14
.
5
%
)
experienced
11
serious
bacterial
infections
over
22
.
0
 
±
 
15
.
0
months
of
treatment
(
0
.
087
events
/
patient
/
year
,
upper
one
-sided
99
%
confidence
interval
:
0
.
170
)
,
the
most
common
being
pneumonia
(
11
.
6
%
)
.
The
rates
for
any
infection
and
hospitalization
were
1
.
082
events
/
patient
/
year
and
3
.
63
days
/
patient
/
year
,
respectively
.
Two
patients
with
severe
disease
accounted
for
303
of
460
hospital
days
.
Across
all
72
patients
,
13
(
18
.
1
%
)
patients
experienced
AEs
,
including
10
(
13
.
9
%
)
patients
with
AEs
at
least
possibly
related
to
Privigen
®
,
including
headache
(
8
.
3
%
)
,
fever
,
and
chills
(
2
.
8
%
each
)
.
No
related
serious
AEs
were
reported
.
One
infant
with
SCID
died
due
to
severe
viral
infection
.
Despite
the
heterogeneous
population
,
effectiveness
and
tolerability
of
Privigen
®
in
clinical
practice
closely
matched
those
reported
in
clinical
studies
.
Diseases
Validation
Diseases presenting
"serious bacterial infections"
symptom
severe combined immunodeficiency
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom